AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 131 min read$LIVN

Tezel Ahmet sold $208K of LIVN

Tezel Ahmet (Chief Innovation Officer) sold 2,675 shares of LivaNova PLC (LIVN) at $77.74 ($0.21M total) on 2026-08-11.

Original reporting
SEC EDGAR · Tezel Ahmet
Published Aug 13, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 13, 2026, 8:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$LIVN
Neutral
medium confidence
Mentioned
$LIVN
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LIVNNeutralLow
01

Why it matters

An officer-level open-market sale without a stated 10b5-1 plan can slightly raise scrutiny, but the disclosure alone does not change fundamentals or provide forward-looking guidance.

02

Market read

Traders may monitor for follow-on insider activity, but there is no new operational or financial information in the filing.

03

What to watch

Insider sales are common and can be non-informative; traders typically need corroboration such as repeated sales, large option exercises, or concurrent operational/regulatory news.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-13, transaction dated 2026-08-11

Background

The article is an SEC Form 4 insider transaction disclosure for LivaNova PLC (LIVN).

Company-level read

Ticker impact

$LIVNNeutralMedium confidence
Context

SEC Form 4 shows Tezel Ahmet, LivaNova’s Chief Innovation Officer, sold 2,675 shares for about $207,942 on 2026-08-11.

Expected impact

Likely limited, short-lived sentiment impact; no clear directional signal without follow-on filings or broader news.

Evidence & confidence

The filing discloses the transaction size, price, and that it was not under a pre-arranged 10b5-1 plan, but it does not provide new company performance, guidance, or events.

Market effects

Sector

No sector-level implications; this is company-specific insider trading disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

The sale may reflect diversification, taxes, or personal liquidity needs rather than a negative view on the business, especially since the article provides no accompanying negative company development.

Key entities

  • issuer
    LivaNova PLC

    Company whose insider transaction is disclosed on SEC Form 4.

  • insider
    Tezel Ahmet

    Chief Innovation Officer who sold 2,675 shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

LIVN insider trading history →

Related articles

OCT 23
$LIVNMed

LivaNova PLC: Neuromodulation Publishes Full 36-Month CORE-VNS Results Demonstrating Sustained and Increasing Benefits of LivaNova's VNS Therapy for Drug-Resistant Epilepsy

LivaNova PLC (LIVN) reported 36-month results from the CORE-VNS study, showing a 76% median reduction in seizure frequency for drug-resistant epilepsy patients using its VNS Therapy. The study also found improvements in quality of life, healthcare resource utilization, and seizure severity. The data was published in the journal Neuromodulation.

finanznachrichten.de3 min
OCT 23
$LIVNMedAI 8/10

A nerve-stimulation study found the share reporting seizure-related hospital stays fell 73% over three years.

LivaNova PLC (LIVN) reported that a 36-month study of its VNS Therapy for Drug-Resistant Epilepsy showed a 73% reduction in seizure-related hospitalizations, improved quality of life, and sustained benefits. The CORE-VNS study, published in Neuromodulation, involved 531 participants across 16 countries, with 426 completing follow-up. The company highlights the therapy's long-term effectiveness and safety.

stocktitan.net2 min
AUG 12
$LIVNMedAI 8/10

LivaNova (LIVN) Q2 2026 Earnings Call Transcript

LivaNova (LIVN) reported Q2 2026 revenue of $390.6 million, up 10.8% reported and 9.8% constant currency, and adjusted diluted EPS of $1.26. Adjusted gross margin rose to 71.0%. Full-year 2026 revenue guidance was raised to 8% to 9% constant-currency growth, and adjusted EPS to $4.30 to $4.40, while free cash flow guidance was lowered to $140 million to $160 million.

fool.com6 min
AUG 7
$LIVNMedAI 8/10

LivaNova PLC Q2 2026 Earnings Call Summary

LivaNova PLC reported record Q2 2026 revenue and EPS, citing double-digit growth in Cardiopulmonary and Epilepsy. It raised full-year 2026 guidance to 8% to 9% revenue growth and adjusted EPS to $4.30 to $4.40, while lowering adjusted free cash flow to $140m to $160m. Key drivers included Essenz HLM upgrades, oxygenator share gains, and higher Medicare reimbursement.

yahoo.com7 min